Abstract:Abstract Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets. Mutations of the FMS-like tyrosine kinase 3 ( FLT3 ) gene occur in approximately 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation ( FLT3 -ITD; approximately 25% of all AML cases). FLT3 -ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML. The prognostic value of a FLT3 mutation in the tyrosine kinase domain ( FLT3 -TKD), which has a lower incidence in AML (approximately 7–10% of all cases), is uncertain. Accumulating evidence demonstrates that FLT3 mutational status evolves throughout the disease continuum. This so-called clonal evolution, together with the identification of FLT3 -ITD as a negative prognostic marker, serves to highlight the importance of FLT3 -ITD testing at diagnosis and again at relapse. Earlier identification of FLT3 mutations will help provide a better understanding of the patient’s disease and enable targeted treatment that may help patients achieve longer and more durable remissions. First-generation FLT3 inhibitors developed for clinical use are broad-spectrum, multikinase inhibitors; however, next-generation FLT3 inhibitors are more specific, more potent, and have fewer toxicities associated with off-target effects. Primary and secondary acquired resistance to FLT3 inhibitors remains a challenge and provides a rationale for combining FLT3 inhibitors with other therapies, both conventional and investigational. This review focuses on the pathological and prognostic role of FLT3 mutations in AML, clinical classification of the disease, recent progress with next-generation FLT3 inhibitors, and mechanisms of resistance to FLT3 inhibitors.

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted Mir-150 Nanoparticles.

Targeting FLT3 mutations in AML: review of current knowledge and evidence

FLT3-targeted treatment for acute myeloid leukemia

The Future of Targeting FLT3 Activation in AML

Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Progress of treatment with Fms-like receptor tyrosine kinase-3 inhibitors for acute myelogenous leukemia

Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment

Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors

“Flipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Advances in Clinical Studies of FLT3 Inhibitors in Acute Myeloid Leukemia.

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade